{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-005511","form_type":"8-K","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.900698+00:00","generated_at":"2026-06-18T18:45:42.045546+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ginkgo Bioworks reports 2022 revenue up 52% to $478M; guides 2023 total revenue at least $275M","bullets":["Full year 2022 total revenue $478M (+52% YoY); Foundry $144M (+27%), Biosecurity $334M (+66%).","Adjusted EBITDA loss widened to $(173)M in 2022 from $(106)M in 2021; operating loss $(2.2)B includes $1.9B stock comp.","2023 guidance: 100 new Cell Programs; total revenue at least $275M (Foundry ≥$175M, Biosecurity ≥$100M).","Cash and equivalents over $1.3B; filing extension for 10-K due to becoming large accelerated filer.","Added 59 new Cell Programs in 2022 (90% growth); downstream milestone potential added over $2.0B."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-005511","json":"https://secwatch.observer/filing/0000950170-23-005511.json","markdown":"https://secwatch.observer/filing/0000950170-23-005511.md","text":"https://secwatch.observer/filing/0000950170-23-005511.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000095017023005511/0000950170-23-005511-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000095017023005511/dna-20230301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T18:45:42.045546+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d56466024830f2aeb4d4e466027a1aa9252535e","claim":"Ginkgo Bioworks Holdings, Inc. reported fourth quarter 2022 and year ended December 31, 2022 results: revenue $478 million. Guidance reaffirmed.","evidence_excerpt":"Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results $478 million of total revenue in 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1830214/000095017023005511/0000950170-23-005511-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter 2022 and year ended December 31, 2022"},{"label":"Revenue","value":"$478 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}